Although the authors highlight the financial benefits of switching to the biosimilar, they also stress the importance of identifying specific products by brand name. Biosimilars are not identical to their originator products, but this could be overlooked by relying on International Nonproprietary Names (INNs), which are shared with originators. All biosimilar G-CSFs, and their originator, share the INN filgrastim. Relying on the INN would make accurate pharmacovigilance impossible. In response, the European Organisation for Research and Treatment of Cancer (EORTC) guidelines [3] highlight the need for clinicians to identify specific products, such as Zarzio, by brand name to reduce the incidence of side effects. The guidelines also state that pharmacists should not switch biosimilar brands without informing both physician and patient.

Once these safeguards are in place, and given the safety and efficacy of Zarzio, there are significant cost savings to be made. In London, UK, for example, switching from the originator to Zarzio was associated with an annual saving of GBP 1 million, which was predicted to rise as more patients were switched to Zarzio. In Sweden's Southern Health Care region, the introduction of biosimilar G-CSF was associated with net savings of Euros 2 million, a saving of 4-5% of the total drug budget.

In both these examples, the reduced costs appear to have improved patient access to G-CSF. In the UK, for example, the availability of biosimilar G-CSF in September 2008 resulted in a 13% increase in overall G-CSF use in the first year and a further 17% increase the following year. Alongside this, write Gascón and co-authors, cost savings could be redistributed, improving access to new cancer treatments, and reducing cost saving pressures elsewhere.

In the current financial climate, conclude the authors, biosimilars offer an affordable, safe and effective alternative. 'Increasing adoption of biosimilars should help reduce healthcare budgets and improve access to expensive biological treatments,' they conclude.

Conflict of interest
Several of the authors of the research paper [1] reported conflicts of interest, including having received honoraria from Sandoz for speaking at educational events, congress presentations and attending advisory boards. For more details, see [1].

Editor's comment
Readers interested to learn more about possible cost savings to be made with the use of biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Saving money in the European healthcare systems with biosimilars

If you are interested in contributing a research paper in a similar area to GaBI Journal, please send us your submission here.

Related article

How safe is Zarzio after five years’ clinical experience?

References
1. Gascón P, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer. 2013;21(10):2925-32.
2. Olry de Labry A, et al. Biosimilars in the European market. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1):30-5. doi: 10.5639/gabij.2013.0201.012
3. EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1):47-8. doi: 10.5639/gabij.2013.0201.016

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.